Compare AbCellera Biologics Inc (ABCL) vs MPLX LP (MPLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs MPLX LP — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while MPLX LP trades at $56.91 (market cap $58.36B). The key difference: MPLX LP is far larger — about 24.8× AbCellera Biologics Inc's market cap, and MPLX LP pays a 7.49% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MPLX | |
|---|---|---|
Market Cap | $2.35B | $58.36B |
Sector | Health | Technology |
52-Week High | $8.12 | $59.17 |
52-Week Low | $2.78 | $47.80 |
Enterprise Value | $1.99B | $82.99B |
Dividend Yield | — | 7.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MPLX trades at $56.97, down 0.33% on the day, with a bullish technical signal supported by moving averages and key indicators like ADX. Financially, the company reported strong 2025 results with $11.47B revenue and $4.91B net income, though Q1 2026 EPS missed expectations. Analyst consensus is strongly positive with a $60.60 price target, and the recent $1.08 dividend underscores its income appeal.
The outlook for MPLX remains favorable, driven by its high-yield dividend, stable cash flows from fee-based contracts, and strategic focus on natural gas and NGL services. Key risks include exposure to energy commodity volatility and high debt levels. Upside potential hinges on execution of growth projects and sustained distribution growth amid a supportive midstream environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
